Source comparison
BPC-157 Gut Health Results Timeline: Study vs Clinical Comparison
Preclinical (rat gastric ulcer model) 10 mcg/kg subcutaneous daily Complete ulcer resolution via endoscopy 100% ulcer closure vs 30% placebo 14 days Gold standard for acute injury. Human translation may require longer timelines due to slower epithelial turnove
This comparison does not assign a generated winner or score.
- Preclinical (rat gastric ulcer model)
- 10 mcg/kg subcutaneous daily
- Complete ulcer resolution via endoscopy
- 100% ulcer closure vs 30% placebo
- 14 days
- Gold standard for acute injury. Human translation may require longer timelines due to slower epithelial turnover
- Preclinical (rat IBD model)
- 10 mcg/kg intraperitoneal daily
- Restoration of mucosal barrier (zonulin, occludin expression)
- Zonulin reduced 68% vs baseline
- 21 days
- Demonstrates barrier-specific repair beyond symptom masking
- Ex vivo human biopsy (gastric tissue)
- 1 mcg/mL culture medium
- Re-epithelialization of artificial wounds
- 2.3× faster gap closure vs control
- 48 hours
- Confirms human tissue responsiveness but doesn't account for systemic dosing variables
- Observational (anecdotal human use)
- 250–500 mcg subcutaneous daily
- Subjective symptom improvement
- Variable. 40–60% report noticeable change
- 14–28 days
- Not controlled, lacks objective endpoints, but consistent with Phase 2 timeline